These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 31535085)

  • 1. Myelopoiesis, metabolism and therapy: a crucial crossroads in cancer progression.
    Sica A; Guarneri V; Gennari A
    Cell Stress; 2019 Jul; 3(9):284-294. PubMed ID: 31535085
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Implications of metabolism-driven myeloid dysfunctions in cancer therapy.
    Strauss L; Guarneri V; Gennari A; Sica A
    Cell Mol Immunol; 2021 Apr; 18(4):829-841. PubMed ID: 33077904
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evolution and Targeting of Myeloid Suppressor Cells in Cancer: A Translational Perspective.
    Bleve A; Consonni FM; Porta C; Garlatti V; Sica A
    Cancers (Basel); 2022 Jan; 14(3):. PubMed ID: 35158779
    [TBL] [Abstract][Full Text] [Related]  

  • 4. T-cell-Secreted TNFα Induces Emergency Myelopoiesis and Myeloid-Derived Suppressor Cell Differentiation in Cancer.
    Al Sayed MF; Amrein MA; Bührer ED; Huguenin AL; Radpour R; Riether C; Ochsenbein AF
    Cancer Res; 2019 Jan; 79(2):346-359. PubMed ID: 30389698
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Myeloid suppressor cells in cancer and autoimmunity.
    Sica A; Massarotti M
    J Autoimmun; 2017 Dec; 85():117-125. PubMed ID: 28728794
    [TBL] [Abstract][Full Text] [Related]  

  • 6. On the origin of myeloid-derived suppressor cells.
    Millrud CR; Bergenfelz C; Leandersson K
    Oncotarget; 2017 Jan; 8(2):3649-3665. PubMed ID: 27690299
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Can interruption of innate immune recognition-mediated emergency myelopoiesis impede tumor progression?
    Mallick R; Duttaroy AK
    Med Hypotheses; 2021 Oct; 155():110663. PubMed ID: 34403869
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of fish oil and corn oil diets on prostaglandin-dependent and myelopoiesis-associated immune suppressor mechanisms of mice bearing metastatic Lewis lung carcinoma tumors.
    Young MR; Young ME
    Cancer Res; 1989 Apr; 49(8):1931-6. PubMed ID: 2522813
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Myelopoiesis-associated suppressor-cell activity in mice with Lewis lung carcinoma tumors: interferon-gamma plus tumor necrosis factor-alpha synergistically reduce suppressor cell activity.
    Young MR; Young ME; Wright MA
    Int J Cancer; 1990 Aug; 46(2):245-50. PubMed ID: 2143498
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting myeloid cells in the tumor sustaining microenvironment.
    Schupp J; Krebs FK; Zimmer N; Trzeciak E; Schuppan D; Tuettenberg A
    Cell Immunol; 2019 Sep; 343():103713. PubMed ID: 29129292
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cutting edge: LPS-induced emergency myelopoiesis depends on TLR4-expressing nonhematopoietic cells.
    Boettcher S; Ziegler P; Schmid MA; Takizawa H; van Rooijen N; Kopf M; Heikenwalder M; Manz MG
    J Immunol; 2012 Jun; 188(12):5824-8. PubMed ID: 22586037
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Energy metabolism drives myeloid-derived suppressor cell differentiation and functions in pathology.
    Sica A; Strauss L
    J Leukoc Biol; 2017 Aug; 102(2):325-334. PubMed ID: 28223316
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cancer-induced systemic myeloid dysfunction: Implications for treatment and a novel nanoparticle approach for its correction.
    Alvarez R; Oliver L; Valdes A; Mesa C
    Semin Oncol; 2018 Jan; 45(1-2):84-94. PubMed ID: 30318088
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Myeloid-derived suppressor cells: The green light for myeloma immune escape.
    Malek E; de Lima M; Letterio JJ; Kim BG; Finke JH; Driscoll JJ; Giralt SA
    Blood Rev; 2016 Sep; 30(5):341-8. PubMed ID: 27132116
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Myelopoiesis in the Context of Innate Immunity.
    Mitroulis I; Kalafati L; Hajishengallis G; Chavakis T
    J Innate Immun; 2018; 10(5-6):365-372. PubMed ID: 29874678
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor-associated myeloid cells: new understandings on their metabolic regulation and their influence in cancer immunotherapy.
    Porta C; Sica A; Riboldi E
    FEBS J; 2018 Feb; 285(4):717-733. PubMed ID: 28985035
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Engagement Between MDSCs and Metastases: Partners in Crime.
    Trovato R; Canè S; Petrova V; Sartoris S; Ugel S; De Sanctis F
    Front Oncol; 2020; 10():165. PubMed ID: 32133298
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor-derived osteopontin suppresses antitumor immunity by promoting extramedullary myelopoiesis.
    Kim EK; Jeon I; Seo H; Park YJ; Song B; Lee KA; Jang Y; Chung Y; Kang CY
    Cancer Res; 2014 Nov; 74(22):6705-16. PubMed ID: 25273090
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of myeloid-derived suppressor cells (MDSC) in the inflammaging process.
    Salminen A; Kaarniranta K; Kauppinen A
    Ageing Res Rev; 2018 Dec; 48():1-10. PubMed ID: 30248408
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting Suppressive Myeloid Cells Potentiates Checkpoint Inhibitors to Control Spontaneous Neuroblastoma.
    Mao Y; Eissler N; Blanc KL; Johnsen JI; Kogner P; Kiessling R
    Clin Cancer Res; 2016 Aug; 22(15):3849-59. PubMed ID: 26957560
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.